Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Start-Up Spotlight: Efemoral Begins Trial Of Peripheral Stent With Inter-Scaffold Gaps

Executive Summary

The EFEMORAL I trial is the first-in-human study of the start-up company’s FlexStep technology in patients with symptomatic femoropopliteal artery disease.

You may also be interested in...



Abbott Launches Trial Of First-Of-A-Kind Resorbable Scaffold For Critical Limb Ischemia

The Esprit BTK everolimus-eluting resorbable scaffold is designed to treat arteries below the knee. No stents or drug-coated balloons are currently FDA-approved for that indication.

Study Links Paclitaxel To Lower-Leg Amputations

New research links the use of stents and balloons coated with the drug paclitaxel to an increased risk of lower-leg amputation shortly following surgery. The study was conducted by Greek researcher Konstantinos Katsanos, who previously found an increased mortality risk in paclitaxel-treated patients.

Abbott Pulls Absorb Stent Off The Market, Citing Low Sales

Abbott is giving up on selling its first-generation biosorbable coronary stent, which failed to match the performance of contemporary metallic drug-eluting stents in clinical trials. The company says it will continue working on the next-generation biosorbable stents and continue the ongoing trials of Absorb GT1 BVS.

Topics

Related Companies

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel